Company intelligence / Profile preview

ImStem Biotechnology, Inc.

Farmington, Connecticut, United Statesimstem.com ↗

Ownership: Private
Development stage: Phase 1

Overview

ImStem's lead candidate IMS001 (T-MSC) received FDA clearance in March 2020 to proceed to clinical trials for Multiple Sclerosis. The Phase 1/2a clinical trial was initiated in Q3 2021 and is currently ongoing. The therapy is administered intravenously without the need for donor matching.

Therapeutic areas: PulmonologyImmunologyRare DiseasesNeurologyInfectious Diseases
Modalities: Mesenchymal stem cell therapyCell therapy
Industry: Biotech

Drug pipeline

2 assets

IMS001

1 more asset in the full pipeline.

Partnerships

AgeX Therapeutics (licensed pluripotent cell line ESI-053)

Beyond the preview

Go deeper on ImStem Biotechnology, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImStem Biotechnology, Inc..